Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 212 participants.

Also called NCT05885919

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 212 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05885919
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05885919. Randomized; triple masking; primary purpose treatment. Start 2023-07-01 (anticipated); primary completion 2024-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke
Acronym
EARLYS
Condition
Ischemic Stroke, Acute
Condition
Treatment Outcome
Intervention (Drug)
Edaravone Dexborneol Concentrated Solution for injection
Intervention (Drug)
Edaravone Dexborneol placebo
Lead sponsor
Xiangya Hospital of Central South University (class: other)
Collaborator
Jiangsu Simcere Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05885919
Content hash
a5fe68a3b4780e801c6f5b5c6e9b48575e39e95256100b24b93aa729ab5e2189